Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sorafenib before radical prostatectomy in operable prostate cancer
NL-OMON28891Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sorafenib in prostate cancer (PCa), sponsored by Amsterdam University Medical Center. Primary endpoints: PSA response rate, Quantitative change in tumor perfusion and 1 more. Planned start Mar 2006; status: not yet recruiting.
02
Drugs
sorafenib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON28891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28891.